Possible Offer

Feb 26, 2010

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 7744H
Advanced Medical Solutions Grp PLC
26 February 2010
 



For immediate release

26 February 2010

 

 

Advanced Medical Solutions Group plc

(“AMS” or the “Company”)

 

Statement re. Possible Offer

 

The Board of Advanced Medical Solutions Group plc notes the recent announcement by Consort Medical Plc (“Consort”) confirming that it has made an approach for AMS which may or may not lead to an offer being made for AMS.  

 

The Board of AMS can confirm that it did receive an approach with a subsequent verbal indication of a possible price to be offered.  The Board of AMS and Investec confirm that they firmly rejected this approach. Since rejecting this verbal indication the Board of AMS has not received a revised approach nor to date has it received any formal written offer from Consort.

 

The Board of AMS advises shareholders to take no action at this stage. Further announcements will be made as appropriate.

 

Enquiries:

 

Advanced Medical Solutions Group plc

Dr. Don Evans, Chief Executive Officer

 

+44 (0) 1606 545 508

Investec Bank plc (Nominated Adviser)

Gary Clarence

Daniel Adams

 

+44 (0) 20 7597 5970

Buchanan Communications

Mark Court

Stasa Filipic

 

+44 (0) 20 7466 5000

 

 

 

Pursuant to Rule 2.10 of the City Code on Mergers and Acquisitions (the “Code”), AMS confirms that it has 145,016,366 ordinary shares of 5p each (“Ordinary Shares”), in issue and admitted to trading on the AIM market of the London Stock Exchange.

 

Dealing Disclosure Requirements

 

Dealing Disclosure Requirements under the provisions of Rule 8.3 of the Code, require that if any person is, or becomes, “interested” (directly or indirectly) in 1% or more of any class of “relevant securities” of AMS, all “dealings” in any “relevant securities” of that company (including by means of an option in respect of, or a derivative referenced to, any such “relevant securities”), it must be publicly disclosed by no later than 3.30p.m. (London time) on the London business day following the date of the relevant transaction.

 

This requirement will continue until the date on which the offer becomes, or is declared, unconditional to acquire an “interest” in “relevant securities” of AMS, they will be deemed to be a single person for the purpose of Rule 8.3. Under the provisions of Rule 8.1 of the Code, all “dealings” in “relevant securities” of AMS by a potential offeror or by AMS, or by any of their respective “associates”, must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.

 

A disclosure table, giving details of the companies in whose “relevant securities” “dealings” should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel’s website at www.thetakeoverpanel.org.uk. “Interests in securities” arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an “interest” by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative reference to, securities. Terms in quotation marks are defined in the Code, which can also be found on the Panel’s website. If you are in any doubt as to whether or not you are required to disclose a “dealing” under Rule 8, you should consult the Panel.

 

Rule 19.11 disclosure

 

In accordance with Rule 19.11 of the Code, a copy of this Announcement will be published on the AMS website: www.admedsol.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

OFDLLFSSFAIRFII

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.